BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33739080)

  • 1. Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell-Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer.
    Guo Q; Dong Y; Zhang Y; Fu H; Chen C; Wang L; Yang X; Shen M; Yu J; Chen M; Zhang J; Duan Y
    ACS Appl Mater Interfaces; 2021 Mar; 13(12):13990-14003. PubMed ID: 33739080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
    Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
    Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
    Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
    Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
    Lv W; Cheng L; Li B
    Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
    Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
    Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic PEG-coated ROS-sensitive prodrug nanoassemblies for core-shell synergistic chemo-photodynamic therapy.
    Sun B; Chen Y; Yu H; Wang C; Zhang X; Zhao H; Chen Q; He Z; Luo C; Sun J
    Acta Biomater; 2019 Jul; 92():219-228. PubMed ID: 31078764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stent film of paclitaxel presenting extreme accumulation of paclitaxel in tumor tissue and excellent antitumor efficacy after implantation beneath the subcutaneous tumor xenograft in mice.
    Wu K; Liu J; Lei L; Shen Y; Guo S
    Int J Pharm; 2018 Dec; 553(1-2):29-36. PubMed ID: 30267754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
    Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
    Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
    Yang X; Shi X; Ji J; Zhai G
    Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor environment differentiated "nanodepot" programmed for site-specific drug shuttling and combinative therapy on metastatic cancer.
    Dong Q; Zhang H; Han Y; Djamila A; Cheng H; Tang Z; Zhou J; Ding Y
    J Control Release; 2018 Aug; 283():59-75. PubMed ID: 29803613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
    Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
    Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer.
    Shanmugam T; Joshi N; Ahamad N; Deshmukh A; Banerjee R
    Int J Pharm; 2020 Aug; 586():119482. PubMed ID: 32492505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
    Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
    Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
    Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
    Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
    Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
    J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.